New cancer research titled “BRAF Mutation as a Novel Driver of Eosinophilic Cystitis” was recently published in the Cancer Biology & Therapy Journal and includes work by CureMatch Co-Founders Igor F. Tsigelny, Ph.D. and Razelle Kurzrock, M.D. along with colleagues from the San Diego Supercomputer Center and UCSD Moores Cancer Center. This article highlights the role of a specific molecular mutation in eosinophilic cystitis, a rare inflammatory bladder condition. Genetic markers such as BRAF I463T provide some of the best indicators to recommend personalized treatments and improve survival rates.
This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.
Otherwise, you will be redirected to the institutional part of this website.
Thank you for your understanding.